Although NNVC has been PR-ing lately the real catalyst IMO is the announcement of the completion of their "Cgmp" facility around year's end.With trials coming in 2014 (short due to the nature of viral life cycles) NNVC should see quick action with the FDA and then NNVC is off to the races.(at that point the FDA's approval is not only for the one "cide" but they will be checkmated because they will have essentially approved NNVC's entire platform)
With that in mind,NNVC is capable of "curing" a new viral disease application every 3-6 months.

Priority Review vouchers from the FDA for each of their orphan drugs could be sold for 200-400M (like printing their own money)

Kelt